Information Provided By: 
Fly News Breaks for September 25, 2015
ANIP, MNK
Sep 25, 2015 | 07:23 EDT
UBS lowered its price target and estimates on Mallinckrodt (MNK) due to competitive threats to Acthar from ANI Pharmaceuticals (ANIP). The firm believes the hurdles are high for ANI Pharma, but the threat is credible and therefore lowered its price target to $110 from $134 on Mallinckrodt. UBS still sees Mallinckrodt as undervalued and thus reiterated its Buy rating on the shares.
News For MNK;ANIP From the Last 2 Days
There are no results for your query MNK;ANIP
